QGEN — Qiagen NV
NYSE · Life Sciences Tools & Services · Life Sciences Tools & Services
- Latest Close
- $40.1
- 30-Day Move
- -11.8%
- Market Cap
- $8.4B
- Shares Outstanding
- 206,070,000
- P/E Ratio
- 19.78
- P/B Ratio
- 2.77
Qiagen NV
A read-only Alphactor snapshot forQiagen NV. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$40.1
30-Day Move
-11.8%
Market Cap
$8.4B
Shares Outstanding
206,070,000
P/E Ratio
19.78
P/B Ratio
2.77
$40.10
-11.8%last 90 delayed daily bars
90D High
$57.81
90D Low
$38.80
Avg Volume
2,070,999
Gross margin is running at 63.0%, which gives a quick read on operating quality before you open the full model.
Net margin is 20.3%, useful for comparing QGEN against peers in Life Sciences Tools & Services.
QGEN is down 11.8% over the last 30 trading days shown on this page.
Latest operating income is $122M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$27.79
Rule of 40
27.0%
Latest Close
$40.1
30-Day Move
-11.8%
Market Cap
$8.4B
Shares Outstanding
206,070,000
P/E Ratio
19.78
P/B Ratio
2.77
ROE
2.3%
ROA
1.5%
Gross Margin
63.0%
Operating Margin
22.2%
Net Margin
20.3%
Debt / Equity
0.39
Current Ratio
3.61
Dividend Yield
64.8%
Latest Revenue
$540M
Revenue
$540M
Gross Profit
$325M
Operating Income
$122M
Net Income
$108M
Gross Margin
6297.0%
Net Margin
2033.0%
Current Ratio
3.61
Debt / Equity
0.39
Fair Value
$27.79
Upside / Downside
-30.7%
Signal
Overvalued
Implied Growth
6.9%
DCF
$23.27
EPV
$14.10
EV/Rev
$45.99
Growth Assumption
-0.8%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$447M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
3.52
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
1.54x
Rule of 40
27.0%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $2.1B | $576M | $423M | $566M |
| 2023-12-31 | $2.0B | $445M | $341M | $297M |
| 2024-12-31 | $2.0B | $200M | $84M | $502M |
| 2025-12-31 | $2.1B | $520M | $425M | $447M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2025-05-09
--
--
Qube Research & Technologies
Filed 2025-08-14
--
--
Northern Trust
Filed 2025-05-13
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
BlackRock
Filed 2024-05-10
$329M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.